title: Biochemical and immunological status following gene therapy and PEG-ADA therapy for adenosine deaminase (ADA) deficiency.
authors.affiliation: Molecular Immunology Unit, UMDS Guy's Hospital, London, GB.
authors.forename: L D
authors.initials: LD
authors.lastname: Fairbanks
authors.forename: H A
authors.initials: HA
authors.lastname: Simmonds
authors.forename: P M
authors.initials: PM
authors.lastname: Hoogerbrugge
authors.forename: V W
authors.initials: VW
authors.lastname: van Beusechem
authors.forename: D
authors.initials: D
authors.lastname: Valerio
authors.forename: A
authors.initials: A
authors.lastname: Moseley
authors.forename: R J
authors.initials: RJ
authors.lastname: Levinsky
authors.forename: H B
authors.initials: HB
authors.lastname: Gaspar
authors.forename: G
authors.initials: G
authors.lastname: Morgan
mesh_terms: D000243:Adenosine Deaminase / Q000096:biosynthesis / Q000172:deficiency* / Q000627:therapeutic use*; D005260:Female; D015316:Genetic Therapy; D006412:Hematopoietic Stem Cells; D006801:Humans; D007223:Infant; D011994:Recombinant Proteins / Q000096:biosynthesis; D016511:Severe Combined Immunodeficiency / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D014162:Transfection
chemical_list: D011994:Recombinant Proteins; D000243:Adenosine Deaminase; C051409:pegademase bovine